🇺🇸 FDA

Company profile · Sponsor

Arrowhead

Arrowhead Pharmaceuticals Ireland Limited

ARWR · NYSE pharma PASADENA, CA, GB
Pipeline
24
Drugs
2
Patents
8

Quick answer

Arrowhead (ARWR) is a pharma company. headquartered in PASADENA, CA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker ARWR
Exchange NYSE
Company type pharma
Headquarters PASADENA, CA, GB
SEC CIK 0000879407

Pipeline (24)

Search pipeline →

  1. ARO-APOC3 PFS

    Arrowhead

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  2. ARO-APOC3 PFS, ARO-APOC3, 0.9% Normal Saline for injection

    Arrowhead

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  3. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  4. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead

    Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  5. Calcium carbonate

    Arrowhead

    Uterine Contraction

    phase 3 small molecule completed

    1 trial

  6. Placebo of Zodasiran, ARO-ANG3

    Arrowhead

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule active

    1 trial

  7. Plozasiran

    Arrowhead

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  8. Plozasiran

    Arrowhead

    Familial Chylomicronemia

    phase 3 small molecule active

    1 trial

  9. Plozasiran

    Arrowhead

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    1 trial

  10. Plozasiran Injection

    Arrowhead

    Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  11. Plozasiran Injection

    Arrowhead

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  12. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  13. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  14. Statins

    Arrowhead

    Intracerebral Hemorrhage

    phase 3 small molecule active

    1 trial

  15. Tranexamic Acid

    Arrowhead

    Hemorrhagic Shock

    phase 3 small molecule completed

    1 trial

  16. Venofer 200 MG Per 10 ML Injection

    Arrowhead

    Iron Deficiency Anemia of Pregnancy

    phase 3 small molecule active

    1 trial

  17. Zodasiran

    Arrowhead

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  18. zodasiran Injection

    Arrowhead

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  19. 0.9% Sodium chloride - inhalation solution

    Arrowhead

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  20. 0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

    Arrowhead

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  21. ARC-520

    Arrowhead

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  22. ARC-520

    Arrowhead

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  23. ARC-520

    Arrowhead

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  24. ARC-520 Injection

    Arrowhead

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

Drugs (2)

Search drugs →

  1. plozasiran

    REDEMPLO

    C10AX

  2. plozasiran sodium

    REDEMPLO

    SUBCUTANEOUS approved

Patents (8)

Search patents →

  1. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12365899

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12188017

    Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12173086

    Alpha-v beta-6 integrin ligands and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12116573

    Targeting ligands for therapeutic compounds

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Arrowhead?

Arrowhead (ARWR) is a pharma company. headquartered in PASADENA, CA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Arrowhead sponsor?

We track 24 ClinicalTrials.gov-linked programs for Arrowhead, including ARO-APOC3 PFS and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Arrowhead company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.